|
1
|
Shimizu T, Kido A, Honoki K, Murata K,
Fujii H, Higuchi B, Ishihara T, Takeshita Y, Shima M, Yajima H, et
al: A successful reconstruction using a frozen autograft and a
pedicled latissimus dorsi flap after a S12345B shoulder girdle
resection in a patient with osteosarcoma. J Reconstr Microsurg.
28:155–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qiu Q, Jiang J, Lin L, Cheng S, Xin D,
Jiang W, Shen J and Hu Z: Downregulation of RSK2 influences the
biological activities of human osteosarcoma cells through
inactivating AKT/mTOR signaling pathways. Int J Oncol.
48:2508–2520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hurley C, McCarville MB, Shulkin BL, Mao
S, Wu J, Navid F, Daw NC, Pappo AS and Bishop MW: Comparison of
(18) F-FDG-PET-CT and bone scintigraphy for evaluation of osseous
metastases in newly diagnosed and recurrent osteosarcoma. Pediatr
Blood Cancer. 63:1381–1386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waresijiang N, Sun J, Abuduaini R, Jiang
T, Zhou W and Yuan H: The downregulation of miR 125a 5p functions
as a tumor suppressor by directly targeting MMP 11 in osteosarcoma.
Mol Med Rep. 13:4859–4864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeng W, Liu Q, Chen Z, Wu X, Zhong Y and
Wu J: Silencing of hERG1 gene inhibits proliferation and invasion,
and induces apoptosis in human osteosarcoma cells by targeting the
NF-κB Pathway. J Cancer. 7:746–757. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun Y, Xia P, Zhang H, Liu B and Shi Y:
P53 is required for Doxorubicin-induced apoptosis via the TGF-beta
signaling pathway in osteosarcoma-derived cells. Am J Cancer Res.
6:114–125. 2015.PubMed/NCBI
|
|
7
|
Zheng K, Yu X, Chang Z, Xu S and Xu M:
Effect of pathological fracture on limb salvage surgery with
preservation of the epiphysis in children with osteosarcoma of the
distal femur: Two case reports. Mol Clin Oncol. 4:523–526. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao J, Chen F, Zhou Q, Pan W, Wang X, Xu
J, Ni L and Yang H: Aberrant expression of microRNA-99a and its
target gene mTOR associated with malignant progression and poor
prognosis in patients with osteosarcoma. Onco Targets Ther.
9:1589–1597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhai J, Qu S, Li X, Zhong J, Chen X, Qu Z
and Wu D: miR-129 suppresses tumor cell growth and invasion by
targeting PAK5 in hepatocellular carcinoma. Biochem Biophys Res
Commun. 464:161–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao ZQ, Zhang CC, Xiao YZ, Zhou JS, Tao YS
and Chai DM: Over-expression of Sox4 and β-catenin is associated
with a less favorable prognosis of osteosarcoma. J Huazhong Univ
Sci Technolog Med Sci. 36:193–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maximov VV and Aqeilan RI: Genetic factors
conferring metastasis in osteosarcoma. Future Oncol. 12:1623–1644.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou Q, Shen L, Liu C, Liu C, Chen H and
Liu J: The effects of estradiol and glucocorticoid on human
osteosarcoma cells: Similarities and differences. Anticancer Res.
36:1683–1691. 2016.PubMed/NCBI
|
|
13
|
Dai Y, Jiang J, Wang Y, Jin Z and Hu S:
The correlation and clinical implication of VEGF-C expression in
microvascular density and lymph node metastasis of gastric
carcinoma. Am J Transl Res. 8:5741–5747. 2016.PubMed/NCBI
|
|
14
|
Huang JF, Du WX and Chen JJ: Elevated
expression of matrix metalloproteinase-3 in human osteosarcoma and
its association with tumor metastasis. J BUON. 21:1279–1286.
2016.PubMed/NCBI
|
|
15
|
Li Y, Ke Q, Shao Y, Zhu G, Li Y, Geng N,
Jin F and Li F: GATA1 induces epithelial-mesenchymal transition in
breast cancer cells through PAK5 oncogenic signaling. Oncotarget.
6:4345–4356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gu X, Wang C, Wang X, Ma G, Li Y, Cui L,
Chen Y, Zhao B and Li K: Efficient inhibition of human glioma
development by RNA interference-mediated silencing of PAK5. Int J
Biol Sci. 11:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan D, Wang S, Ye H, Xu S and Ye G: Ezrin
expression in the primary hepatocellular carcinoma patients and
associated with clinical, pathological characteristics. J Cancer
Res Ther. 12:291–294. 2016. View Article : Google Scholar
|
|
18
|
Du P, Xu B, Zhang D, Shao Y, Zheng X, Li
X, Xiong Y, Wu C and Jiang J: Hierarchical investigating the
predictive value of p53, COX2, EGFR, nm23 in the post-operative
patients with colorectal carcinoma. Oncotarget. 8:954–966.
2017.PubMed/NCBI
|
|
19
|
Rox K, Rohde M, Chhatwal GS and Müller R:
Disorazoles block group A streptococcal invasion into epithelial
cells via interference with the host factor Ezrin. Cell Chem Biol.
24:159–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hago AM, Gamallat Y, Mahmoud SA, Huang Y,
Zhang J, Mahmoud YK, Wang J, Wei Y, Wang L, Zhou S, et al: Ezrin
expression is altered in mice lymphatic metastatic hepatocellular
carcinoma and subcellular fractions upon Annexin 7 modulation
in-vitro. Biomed Pharmacother. 85:209–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
